Novavax COVID-19 vaccine has been found to be 96% effective in preventing COVID-19 cases due to the original version of the coronavirus in a late-stage trial in the United Kingdom, reported the company.

No cases of severe illness or deaths were evident among those given the vaccine. Additionally, the vaccine had an efficacy of 86% in protecting against the more contagious variant first detected in the United Kingdom. The combined effectiveness rate based on data from infections due to both versions of the coronavirus was estimated as 90%.

A smaller trial in South Africa, where people were exposed to another new, more contagious variant widely prevalent there, noted that the Novavax vaccine was 55% effective, based on people without HIV. However, the vaccine still completely prevented severe illness… (Mint, March 12, 2021)